Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Aspen Pharmacare Holdings's Revenue for the
six
months ended in Dec. 2025 was R17,078 Mil. Aspen Pharmacare Holdings's average Accounts Receivable for the
six
months ended in Dec. 2025 was R10,358 Mil.
Hence, Aspen Pharmacare Holdings's Receivables Turnover for the
six
months ended in Dec. 2025 was 1.65.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Aspen Pharmacare Holdings Receivables Turnover Related Terms
Aspen Pharmacare Holdings Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:APN vs ZTS, UTHR, VTRS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspen Pharmacare Holdings Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Aspen Pharmacare Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspen Pharmacare Holdings (JSE:APN) has a Receivables Turnover of 1.65 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Aspen Pharmacare Holdings and its competitors. According to the industry distribution chart, Aspen Pharmacare Holdings ranks #663 out of 950 companies in the Drug Manufacturers industry, placing it in the top 69.8%.
Is Aspen Pharmacare Holdings' Receivables Turnover too high?
Aspen Pharmacare Holdings' current Receivables Turnover is 1.65. The Drug Manufacturers industry median Receivables Turnover is 5.07. Aspen Pharmacare Holdings' value of 1.65 is 67.5% below this industry median. Based on the distribution chart, Aspen Pharmacare Holdings ranks #663 out of 950 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Aspen Pharmacare Holdings has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aspen Pharmacare Holdings ranks #663 out of 950 companies for Receivables Turnover. This places Aspen Pharmacare Holdings in the lower half of its industry. The industry median Receivables Turnover is 5.07. Aspen Pharmacare Holdings' value of 1.65 is 67.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspen Pharmacare Holdings's current Receivables Turnover of 1.65 is 67.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Aspen Pharmacare Holdings and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspen Pharmacare Holdings's current Receivables Turnover is 1.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (JSE:APN) is currently considered Modestly Undervalued. The stock's GF Value™ is R167.43, compared to a current price of R148.00 — trading 11.6% below its estimated fair value. The current Receivables Turnover is 1.65 and 67.5% below the Drug Manufacturers industry median of 5.07. Aspen Pharmacare Holdings' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Aspen Pharmacare Holdings (JSE:APN), the current Receivables Turnover is 1.65 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspen Pharmacare Holdings (JSE:APN) Overvalued in 2026?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued.
The current stock price of R148.00 is trading 11.6% below its estimated GF Value™ of R167.43.
GuruFocus considers Aspen Pharmacare Holdings to be Modestly Undervalued.
Key valuation signals for JSE:APN:
Receivables Turnover: 1.65
GF Value™: R167.43 vs. price of R148.00 (11.6% below fair value)
Industry Position: 67.5% below the Drug Manufacturers median (#663 of 950)
No single metric tells the full story. See the JSE:APN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
73GF Score
Get the complete analysis for JSE:APN
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:APN has been successfully added to your 
